PBPK modeling and simulation in drug research and development

被引:0
|
作者
Xiaomei Zhuang [1 ]
Chuang Lu [2 ]
机构
[1] State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacology and Toxicology
[2] Department of DMPK,Biogen,Inc.
关键词
PBPK; PK prediction; Absorption; Metabolism; Drug–drug interaction; Special population;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Physiologically based pharmacokinetic(PBPK) modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data.It can also explore the effects of various physiologic parameters such as age,ethnicity,or disease status on human pharmacokinetics,as well as guide dose and dose regiment selection and aid drug–drug interaction risk assessment.PBPK modeling has developed rapidly in the last decade within both the field of academia and the pharmaceutical industry,and has become an integral tool in drug discovery and development.In this mini-review,the concept and methodology of PBPK modeling are briefly introduced.Several case studies were discussed on how PBPK modeling and simulation can be utilized through various stages of drug discovery and development.These case studies are from our own work and the literature for better understanding of the absorption,distribution,metabolism and excretion(ADME) of a drug candidate,and the applications to increase efficiency,reduce the need for animal studies,and perhaps to replace clinical trials.The regulatory acceptance and industrial practices around PBPK modeling and simulation is also discussed.
引用
收藏
页码:430 / 440
页数:11
相关论文
共 50 条
  • [1] PBPK modeling and simulation in drug research and development
    Zhuang, Xiaomei
    Lu, Chuang
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 430 - 440
  • [2] Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
    Shaik, Abdul Naveed
    Khan, Ansar Ali
    ADMET AND DMPK, 2019, 7 (01): : 1 - 3
  • [3] Unleashing PBPK Modeling Potential in Pediatric Drug Development
    Zhang, Liping
    Su, Yaming
    CURRENT PHARMACOLOGY REPORTS, 2024, 10 (06) : 277 - 288
  • [4] PBPK Modeling to Guide Experimental Design in Drug Development
    Dickschen, Kristin
    Jaeger, Juergen
    Hutt, Meike
    Pollak, Nadine
    Siegemund, Martin
    Seifert, Oliver
    Kontermann, Roland
    Pfizenmaier, Klaus
    Block, Michael
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S75 - S75
  • [5] Development and application of a PBPK modeling strategy to support antimalarial drug development
    Abla, Nada
    Howgate, Eleanor
    Rowland-Yeo, Karen
    Dickins, Maurice
    Bergagnini-Kolev, Mackenzie C. C.
    Chen, Kuan-Fu
    McFeely, Savannah
    Bonner, Jennifer J. J.
    Santos, Laura G. A.
    Gobeau, Nathalie
    Burt, Howard
    Barter, Zoe
    Jones, Hannah M. M.
    Wesche, David
    Charman, Susan A. A.
    Moehrle, Jorg J.
    Burrows, Jeremy N. N.
    Almond, Lisa M. M.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (09): : 1335 - 1346
  • [6] PBPK Modeling: Empowering Drug Development and Precision Dosing in China
    Yang, Dongsheng
    Li, Jian
    Mak, Wen Yao
    Zheng, Aole
    Zhu, Xiao
    He, Qingfeng
    Wang, Yuzhu
    Xiang, Xiaoqiang
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025,
  • [7] Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute
    Smits, Anne
    De Cock, Pieter
    Vermeulen, An
    Allegaert, Karel
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (01) : 25 - 34
  • [8] Modelling and PBPK Simulation in Drug Discovery
    Jones, Hannah M.
    Gardner, Iain B.
    Watson, Kenny J.
    AAPS JOURNAL, 2009, 11 (01): : 155 - 166
  • [9] Modelling and PBPK Simulation in Drug Discovery
    Hannah M. Jones
    Iain B. Gardner
    Kenny J. Watson
    The AAPS Journal, 2009, 11 : 155 - 166
  • [10] Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole
    Shah, Harsh
    Shah, Kushal
    Gajera, Bhavin
    Dave, Rutesh H.
    Taft, David R.
    PHARMACEUTICS, 2023, 15 (04)